CEP-40125

• Description:

  CEP-40125 (RXDX-107) is a modified form of Bendamustine (HY-13567), a DNA cross-linking agent that may cause DNA damage and cell apoptosis. CEP-40125 (RXDX-107) is formed by encapsulating the alkyl ester form of Bendamustine in human serum albumin[1][2].

• Product Name Alternative:

  RXDX-107

• UNSPSC:

  12352005

• Target:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cep-40125.html

• Smiles:

  O=C(CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C)OCCCCCCCCCCCC

• Molecular Formula:

  C28H45Cl2N3O2

• Molecular Weight:

  526.58

• References & Citations:

  [1]Pharmaceutical prodrugs and methods of their preparation and use. WO2018013783.|[2]Croasdell G. The 34th Annual JP Morgan Healthcare Conference. San Francisco, California, USA-January 11-14, 2016[J]. Drugs of the Future, 2016, 41 (1) .

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [1456608-94-8]